Clinical trials: RA - Rheumatoid Arthritis
Rheumatoid Arthritis
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function.
- Trial name
- NCT07904754
- Testing
- ABBV-722, Upadacitinib
- Volunteers
- 250 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Primary Objective: To demonstrate the treatment effect of sarilumab and methotrexate (MTX) compared to etanercept and MTX in participants with rheumatoid arthritis (RA) and an inadequate response to adalimumab and MTX by…
- Trial name
- RA-COMPARE (NCT01764997)
- Testing
- Sarilumab, Etanercept, Methotrexate
- Where
- 257 sites in United States, Argentina and 29 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.
- Trial name
- NCT00144508
- Testing
- MRA (Tocilizumab), current treatment
- Volunteers
- 306 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis
- Trial name
- NCT03241108
- Testing
- NI-0101
- Where
- 19 sites in Bosnia and Herzegovina, Bulgaria and 5 more
- Volunteers
- 90 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of Iguratimod in Patients With Active Rheumatoid Arthritis
This study is intended to evaluate the safety and efficacy of Iguratimod in patients with active Rheumatoid Arthritis.
- Trial name
- NCT01554917
- Testing
- Iguratimod
- Where
- China
- Volunteers
- 1,759 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment
- Trial name
- NCT00661284
- Where
- 5 sites in Japan
- Volunteers
- 189 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Main Study: Primary Objective: Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA). Secondary Objective: Assess the long term efficacy of sarilumab in participants with RA.
- Trial name
- NCT01146652
- Testing
- SAR153191 (REGN88)
- Where
- 335 sites in United States, Argentina and 38 more
- Volunteers
- 2,023 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.
- Trial name
- NCT01034306
- Testing
- CF101
- Where
- 5 sites in Bulgaria, Israel
- Volunteers
- 79 people
- Sponsor
- Can-Fite BioPharma
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a…
- Trial name
- OSKIRA - 3 (NCT01197755)
- Testing
- fostamatinib
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 323 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT01194414
- Testing
- tocilizumab SC, tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 216 sites in United States, Argentina and 24 more
- Volunteers
- 1,262 people
- Sponsor
- Hoffmann-La Roche
Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
- Trial name
- NCT06025578
- Testing
- BMS-986278
- Where
- 459 sites in United States, Argentina and 33 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).
- Trial name
- NCT00095498
- Testing
- denosumab
- Volunteers
- 227 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Treatment for Subjects With Active Rheumatoid Arthritis (RA)
The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.
- Trial name
- NCT00110903
- Testing
- Etanercept Liquid
- Sponsor
- Amgen
Arthritis, Rheumatoid Arthritis
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to…
- Trial name
- NCT01009242
- Testing
- CDP6038, CDP 6038 SC, Methotrexate
- Where
- 6 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate
This study assessed the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and…
- Trial name
- NCT00619905
- Testing
- ACZ885
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 53 people
- Sponsor
- Novartis
Rheumatoid Arthritis
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.
- Trial name
- NCT04246762
- Testing
- Olokizumab, Omeprazole, Caffeine
- Where
- 2 sites in Bulgaria, Moldova
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
This is a two-stage study of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of various doses of levilimab when administered intravenously and subcutaneously to healthy subjects and subjects with active…
- Trial name
- NCT05800327
- Testing
- Levilimab
- Where
- Russia
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- Biocad
Rheumatoid Arthritis
Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056
The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina
- Trial name
- NCT00700986
- Testing
- AZD9056
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.